These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29141849)

  • 21. Polycystic Ovary Syndrome in Adolescents.
    Witchel SF; Roumimper H; Oberfield S
    Endocrinol Metab Clin North Am; 2016 Jun; 45(2):329-44. PubMed ID: 27241968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome.
    Ezeh U; Pisarska MD; Azziz R
    Hum Reprod; 2022 Mar; 37(3):553-564. PubMed ID: 35048126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism.
    Ezeh U; Ezeh C; Pisarska MD; Azziz R
    Fertil Steril; 2021 Jun; 115(6):1557-1568. PubMed ID: 33602559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of cancer treatment on risk of infertility and diminished ovarian reserve in women with polycystic ovary syndrome.
    Shandley LM; Fothergill A; Spencer JB; Mertens AC; Cottrell HN; Howards PP
    Fertil Steril; 2018 Mar; 109(3):516-525.e1. PubMed ID: 29428311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial ovarian cancer risk among women with polycystic ovary syndrome.
    Schildkraut JM; Schwingl PJ; Bastos E; Evanoff A; Hughes C
    Obstet Gynecol; 1996 Oct; 88(4 Pt 1):554-9. PubMed ID: 8841217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Has oligomenorrhea a pathological meaning? The importance of this symptom in internal medicine].
    Devoto E; Aravena L; Gaete X
    Rev Med Chil; 1998 Aug; 126(8):943-51. PubMed ID: 9830746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium.
    Cannioto R; LaMonte MJ; Risch HA; Hong CC; Sucheston-Campbell LE; Eng KH; Brian Szender J; Chang-Claude J; Schmalfeldt B; Klapdor R; Gower E; Minlikeeva AN; Zirpoli GR; Bandera EV; Berchuck A; Cramer D; Doherty JA; Edwards RP; Fridley BL; Goode EL; Goodman MT; Hogdall E; Hosono S; Jensen A; Jordan S; ; Kjaer SK; Matsuo K; Ness RB; Olsen CM; Olson SH; Leigh Pearce C; Pike MC; Anne Rossing M; Szamreta EA; Thompson PJ; Tseng CC; Vierkant RA; Webb PM; Wentzensen N; Wicklund KG; Winham SJ; Wu AH; Modugno F; Schildkraut JM; Terry KL; Kelemen LE; Moysich KB
    Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1114-24. PubMed ID: 27197285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for epithelial ovarian tumours of borderline malignancy.
    Parazzini F; Restelli C; La Vecchia C; Negri E; Chiari S; Maggi R; Mangioni C
    Int J Epidemiol; 1991 Dec; 20(4):871-7. PubMed ID: 1800425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus.
    Solomon CG; Hu FB; Dunaif A; Rich-Edwards J; Willett WC; Hunter DJ; Colditz GA; Speizer FE; Manson JE
    JAMA; 2001 Nov; 286(19):2421-6. PubMed ID: 11712937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pelvic inflammatory disease and risk of epithelial ovarian cancer: a national population-based case-control study in Sweden.
    Jonsson S; Jonsson H; Lundin E; Häggström C; Idahl A
    Am J Obstet Gynecol; 2024 Jan; 230(1):75.e1-75.e15. PubMed ID: 37778677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic implications of menstrual cycle length in non-hyperandrogenic women with polycystic ovarian morphology.
    Alebić MŠ; Stojanović N; Baldani DP; Duvnjak LS
    Endocrine; 2016 Dec; 54(3):798-807. PubMed ID: 27484772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Different types of menstrual cycle and their significance in Chinese women diagnosed with polycystic ovary syndrome according to the Rotterdam consensus criteria].
    Xu XH; Tan YC; Shi YH; Wang B; Ju XQ; Zheng QM; Hao CF; Chen ZJ
    Zhonghua Yi Xue Za Zhi; 2009 Oct; 89(37):2604-6. PubMed ID: 20137675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case-control studies.
    Faber MT; Kjær SK; Dehlendorff C; Chang-Claude J; Andersen KK; Høgdall E; Webb PM; Jordan SJ; ; ; Rossing MA; Doherty JA; Lurie G; Thompson PJ; Carney ME; Goodman MT; Ness RB; Modugno F; Edwards RP; Bunker CH; Goode EL; Fridley BL; Vierkant RA; Larson MC; Schildkraut J; Cramer DW; Terry KL; Vitonis AF; Bandera EV; Olson SH; King M; Chandran U; Kiemeney LA; Massuger LF; van Altena AM; Vermeulen SH; Brinton L; Wentzensen N; Lissowska J; Yang HP; Moysich KB; Odunsi K; Kasza K; Odunsi-Akanji O; Song H; Pharaoh P; Shah M; Whittemore AS; McGuire V; Sieh W; Sutphen R; Menon U; Gayther SA; Ramus SJ; Gentry-Maharaj A; Pearce CL; Wu AH; Pike MC; Risch HA; Jensen A;
    Cancer Causes Control; 2013 May; 24(5):989-1004. PubMed ID: 23456270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study.
    Risch HA; Marrett LD; Jain M; Howe GR
    Am J Epidemiol; 1996 Aug; 144(4):363-72. PubMed ID: 8712193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years.
    Bili H; Laven J; Imani B; Eijkemans MJ; Fauser BC
    Eur J Endocrinol; 2001 Dec; 145(6):749-55. PubMed ID: 11720900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies.
    Sieh W; Salvador S; McGuire V; Weber RP; Terry KL; Rossing MA; Risch H; Wu AH; Webb PM; Moysich K; Doherty JA; Felberg A; Miller D; Jordan SJ; ; ; Goodman MT; Lurie G; Chang-Claude J; Rudolph A; Kjær SK; Jensen A; Høgdall E; Bandera EV; Olson SH; King MG; Rodriguez-Rodriguez L; Kiemeney LA; Marees T; Massuger LF; van Altena AM; Ness RB; Cramer DW; Pike MC; Pearce CL; Berchuck A; Schildkraut JM; Whittemore AS;
    Int J Epidemiol; 2013 Apr; 42(2):579-89. PubMed ID: 23569193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired uterine perfusion associated with metabolic disorders in women with polycystic ovary syndrome.
    Chekir C; Nakatsuka M; Kamada Y; Noguchi S; Sasaki A; Hiramatsu Y
    Acta Obstet Gynecol Scand; 2005 Feb; 84(2):189-95. PubMed ID: 15683382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unexpected effect of a nitric oxide donor on uterine artery Doppler velocimetry in oligomenorrheic women with polycystic ovaries.
    Lees C; Jurkovic D; Zaidi J; Campbell S
    Ultrasound Obstet Gynecol; 1998 Feb; 11(2):129-32. PubMed ID: 9549840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oligomenorrhoea in exercising women: a polycystic ovarian syndrome phenotype or distinct entity?
    Awdishu S; Williams NI; Laredo SE; De Souza MJ
    Sports Med; 2009; 39(12):1055-69. PubMed ID: 19902985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents.
    Villarroel C; López P; Merino PM; Iñiguez G; Sir-Petermann T; Codner E
    Gynecol Endocrinol; 2015; 31(8):625-9. PubMed ID: 26190534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.